UY38006A - Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones - Google Patents

Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Info

Publication number
UY38006A
UY38006A UY0001038006A UY38006A UY38006A UY 38006 A UY38006 A UY 38006A UY 0001038006 A UY0001038006 A UY 0001038006A UY 38006 A UY38006 A UY 38006A UY 38006 A UY38006 A UY 38006A
Authority
UY
Uruguay
Prior art keywords
therapy
compounds
mtor
kinasa
inhibitors
Prior art date
Application number
UY0001038006A
Other languages
English (en)
Inventor
Gianpaolo Bravi
Heather Hobbs
Graham George Adam Inglis
Simon Nicolle
Simon Peace
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY38006A publication Critical patent/UY38006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I): en donde R1, R2, R3, R4, L y A se definen en la descripción y las reivindicaciones, o las sales farmacéuticamente aceptables de los mismos que tienen actividad inhibidora de la quinasa mTOR. La invención también se refiere a composiciones farmacéuticas que incluyen un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo, y al uso de un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo en terapia.
UY0001038006A 2017-12-15 2018-12-13 Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones UY38006A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720989.1A GB201720989D0 (en) 2017-12-15 2017-12-15 Chemical compounds

Publications (1)

Publication Number Publication Date
UY38006A true UY38006A (es) 2019-07-31

Family

ID=61008661

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038006A UY38006A (es) 2017-12-15 2018-12-13 Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Country Status (11)

Country Link
US (1) US11254671B2 (es)
EP (1) EP3724187A1 (es)
JP (1) JP2021506809A (es)
CN (1) CN111491932A (es)
AR (1) AR113935A1 (es)
BR (1) BR112020011988A2 (es)
CA (1) CA3085666A1 (es)
GB (1) GB201720989D0 (es)
TW (1) TW201938161A (es)
UY (1) UY38006A (es)
WO (1) WO2019115640A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243446A1 (en) * 2019-05-30 2020-12-03 Children's Hospital Medical Center Methods and compositions for treatment of smith kingsmore syndrome
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI79651C (fi) 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP2287199B1 (en) 2002-03-13 2017-08-02 Biogen MA Inc. Anti-alpha V beta 6 antibodies
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
JP4825138B2 (ja) 2004-02-16 2011-11-30 グラクソ グループ リミテッド 薬剤ディスペンサー用カウンター
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
AU2007204208A1 (en) * 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
SI2057156T1 (sl) * 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
US20100227858A1 (en) * 2007-07-09 2010-09-09 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
EA201390740A1 (ru) * 2010-11-19 2013-12-30 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Способ лечения с использованием ингибитора braf
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds

Also Published As

Publication number Publication date
CA3085666A1 (en) 2019-06-20
CN111491932A (zh) 2020-08-04
EP3724187A1 (en) 2020-10-21
US20210163472A1 (en) 2021-06-03
US11254671B2 (en) 2022-02-22
BR112020011988A2 (pt) 2020-11-17
TW201938161A (zh) 2019-10-01
JP2021506809A (ja) 2021-02-22
GB201720989D0 (en) 2018-01-31
WO2019115640A1 (en) 2019-06-20
AR113935A1 (es) 2020-07-01

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
BR112016016844A2 (pt) Compostos heterocíclicos
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201991884A2 (ru) Ингибиторы g12c kras
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201690752A1 (ru) Ингибиторы g12c kras
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
EA201890532A1 (ru) Новые аннелированные бензамиды
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones